ARDELYX, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ARDELYX, INC. (ARDX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $25.52 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2020-08-06
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2020-06-30 was $21.52M, a 31.54% decline year-over-year.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2020-03-31 was $4.00M, a 92.73% decline year-over-year.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-06-30 was $31.43M.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-03-31 was $55.02M.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2019 was $124.37M, a 10.27% decline from fiscal 2018.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2018 was $138.60M, a 3.66% increase from fiscal 2017.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $133.70M, a 1659.22% increase from fiscal 2016.
- ARDELYX, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $7.60M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|
| 2020-06-30 | $21.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $25.52M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $4.00M 10-Q · filed 2020-05-07 | ||
| 2019-12-31 | $124.37M 10-K · filed 2020-03-06 | ||
| 2019-06-30 | $31.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $86.45M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $55.02M 10-Q · filed 2020-05-07 | ||
| 2018-12-31 | $138.60M 10-K · filed 2020-03-06 | ||
| 2017-12-31 | $133.70M 10-K · filed 2020-03-06 | ||
| 2016-12-31 | $7.60M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |